<p>随着全球市场应对地缘政治紧张局势和货币政策变化的复杂性，美国股市展现出韧性，主要指数在鹰派的美联储立场和波动的油价背景下仍然录得上涨。在这种情况下，识别高增长科技股需要关注那些在人工智能等领域展现出强劲盈利潜力和创新能力的公司，这些公司有望从当前市场动态中受益。</p>
<h3>全球十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 197 只股票的完整列表。</p>
<p>在这里，我们突出显示了筛选器中我们首选股票的一个子集。</p>
<h2>Pharming Group (ENXTAM:PHARM)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Pharming Group N.V. 是一家生物制药公司，专注于开发和商业化针对罕见疾病的蛋白质替代疗法和精准医疗，业务覆盖美国、欧洲及国际市场，市值为 10.1 亿欧元。</p>
<p><strong>运营：</strong> Pharming Group 的收入主要来自其产品 Joenja® 和 Ruconest®，分别贡献 5821 万美元和 3.1792 亿美元。该公司专注于生物制药领域，致力于罕见疾病，市值约为 10 亿欧元。</p>
<p>Pharming Group 最近的进展和财务增长反映了其在生物技术领域的潜力，特别是其针对 APDS 的开创性治疗 Joenja。该公司报告显示，年度收入从前一年的 2.972 亿美元上升至 3.7613 亿美元，净亏损从 1184 万美元转变为净利润 285 万美元。这一复苏得益于战略性会议展示和积极的临床试验结果，增强了其在欧洲和日本的市场存在。预计每年盈利增长为 36.7%，研发专注于通过创新治疗解决罕见疾病，Pharming 正在将自己定位为专业医疗解决方案的关键参与者。</p>
<ul>
<li>解锁我们对 Pharming Group 股票分析的全面见解，详见此健康报告。</li>
<li>通过查看我们的历史报告了解 Pharming Group 的业绩记录。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2026 年 5 月 ENXTAM:PHARM 收入和支出明细</p>
<h2>CELSYS (TSE:3663)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> CELSYS, Inc. 在日本运营，提供内容创作解决方案，市值约为 398.5 亿日元。</p>
<p><strong>运营：</strong> 该公司专注于在日本提供内容创作解决方案，主要通过软件销售和相关服务产生收入，特别强调数字插图和动画工具。</p>
<p>CELSYS 在其财务运营中展现出韧性和战略前瞻性，尤其体现在其最近的企业行动中，以优化库藏股。预计年盈利增长为 22.3%，收入年增长率为 9.7%，显著超过日本市场的平均水平。这些数据得益于强劲的研发投资，不仅突显了 CELSYS 对创新的承诺，还与行业向更先进数字解决方案的趋势相一致。最近的股息调整反映了对股东回报的战术性方法，在增长再投资和通过预计从每股 14.00 日元提高到 20.00 日元的股息直接提升股东价值之间取得平衡。</p>
<ul>
<li>点击这里深入了解 CELSYS 的完整分析健康报告。</li>
<li>查看我们的历史业绩报告，以获取 CELSYS 过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 5 月 TSE:3663 盈利和收入增长</p>
<h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Plus Alpha Consulting Co., Ltd. 在日本提供市场营销和人力资源解决方案，市值为 923.3 亿日元。</p>
<p><strong>运营：</strong> Plus Alpha Consulting Co., Ltd. 主要通过其人力资源解决方案产生收入，贡献 138.4 亿日元，以及市场营销解决方案，贡献 37.9 亿日元。该公司专注于日本市场，致力于这两个关键领域推动其业务运营。</p>
<p>Plus Alpha ConsultingLtd 最近展现出强劲的财务表现，季度销售额从 38.9 亿日元增加到 44.4 亿日元，净收入从 7.5555 亿日元激增至 11.5 亿日元，同比大幅增长。这一增长轨迹得益于 12.5% 的年收入增长率，显著超过日本市场的平均水平 6%。该公司对创新的承诺体现在其研发支出趋势上，与行业向更复杂数字解决方案的转变相一致，确保在不断发展的科技领域中的竞争力。</p>
<ul>
<li>点击探索 Plus Alpha ConsultingLtd 健康报告中我们发现的详细信息。</li>
<li>了解 Plus Alpha ConsultingLtd 的历史表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown"/></p>
<p>TSE:4071 收入和支出明细截至 2026 年 5 月</p>
<h2>抓住机会</h2>
<ul>
<li>点击此链接深入了解我们全球高增长科技和人工智能股票筛选器中的 197 家公司。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>使用免费的 Simply Wall St 应用程序更智能地投资，提供全球每个股票市场的详细见解。</li>
</ul>
<h2>准备好不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
<p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
<p>• 通过电子邮件或手机接收新警告信号或风险的提醒</p>
<p>• 跟踪您股票的公允价值</p>
<p>免费试用演示投资组合</p>

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

医药突破 ETF - ALPS

全球科技股指数 ETF - iShares

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

<p>随着全球市场面临地缘政治紧张局势和货币政策变化，美国股票依然表现出韧性。高增长的科技股备受关注，尤其是在人工智能等领域。值得注意的公司包括 Pharming Group、CELSYS 和 Plus Alpha Consulting，它们各自在收入和盈利增长方面表现强劲。Pharming Group 报告收入增长至 3.7613 亿美元，净利润为 285 万美元，而 CELSYS 和 Plus Alpha Consulting 在各自市场上也展现出显著的增长。这些公司在当前市场动态中为未来增长奠定了良好的基础</p>

<p>As global markets navigate the complexities of geopolitical tensions and shifting monetary policies, U.S. stocks have shown resilience with major indexes posting gains despite a hawkish Federal Reserve stance and fluctuating oil prices. In this context, identifying high-growth tech stocks involves looking for companies that demonstrate robust earnings potential and innovation in sectors like artificial intelligence, which are poised to benefit from current market dynamics.</p>
<div class="lb-trans"><p>随着全球市场应对地缘政治紧张局势和货币政策变化的复杂性，美国股市展现出韧性，主要指数在鹰派的美联储立场和波动的油价背景下仍然录得上涨。在这种情况下，识别高增长科技股需要关注那些在人工智能等领域展现出强劲盈利潜力和创新能力的公司，这些公司有望从当前市场动态中受益。</p>
</div><h3>Top 10 High Growth Tech Companies Globally</h3>
<div class="lb-trans"><h3>全球十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hacksaw</td>
<td>25.39%</td>
<td>24.90%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Shengyi Electronics</td>
<td>26.78%</td>
<td>32.30%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Delton Technology (Guangzhou)</td>
<td>29.71%</td>
<td>33.06%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Zhongji Innolight</td>
<td>41.90%</td>
<td>44.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Suzhou TFC Optical Communication</td>
<td>44.06%</td>
<td>41.48%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fositek</td>
<td>29.55%</td>
<td>39.17%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Unimicron Technology</td>
<td>29.87%</td>
<td>54.56%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>KebNi</td>
<td>26.87%</td>
<td>82.69%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Co-Tech Development</td>
<td>34.37%</td>
<td>65.79%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CARsgen Therapeutics Holdings</td>
<td>64.21%</td>
<td>83.56%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 197 stocks from our Global High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球高增长科技和人工智能股票筛选器中的 197 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出显示了筛选器中我们首选股票的一个子集。</p>
</div><h2>Pharming Group (ENXTAM:PHARM)</h2>
<div class="lb-trans"><h2>Pharming Group (ENXTAM:PHARM)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Pharming Group N.V. is a biopharmaceutical company that focuses on developing and commercializing protein replacement therapies and precision medicines for rare diseases across the United States, Europe, and internationally, with a market cap of €1.01 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Pharming Group N.V. 是一家生物制药公司，专注于开发和商业化针对罕见疾病的蛋白质替代疗法和精准医疗，业务覆盖美国、欧洲及国际市场，市值为 10.1 亿欧元。</p>
</div><p><strong>Operations:</strong> Pharming Group generates revenue primarily from its products Joenja® and Ruconest®, contributing $58.21 million and $317.92 million, respectively. The company is involved in the biopharmaceutical sector, focusing on rare diseases with a market cap of approximately €1 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> Pharming Group 的收入主要来自其产品 Joenja® 和 Ruconest®，分别贡献 5821 万美元和 3.1792 亿美元。该公司专注于生物制药领域，致力于罕见疾病，市值约为 10 亿欧元。</p>
</div><p>Pharming Group's recent advancements and financial growth reflect its potential in the biotech sector, particularly with its pioneering treatment, Joenja, for APDS. The company reported a significant turnaround with annual revenue rising to $376.13 million, up from $297.2 million the previous year, and transitioning from a net loss of $11.84 million to a net profit of $2.85 million. This resurgence is bolstered by strategic conference presentations and positive clinical trial outcomes that enhance its market presence in Europe and Japan. With an expected earnings growth of 36.7% per year and R&amp;D focused on addressing rare diseases through innovative treatments, Pharming is positioning itself as a key player in specialized healthcare solutions.</p>
<div class="lb-trans"><p>Pharming Group 最近的进展和财务增长反映了其在生物技术领域的潜力，特别是其针对 APDS 的开创性治疗 Joenja。该公司报告显示，年度收入从前一年的 2.972 亿美元上升至 3.7613 亿美元，净亏损从 1184 万美元转变为净利润 285 万美元。这一复苏得益于战略性会议展示和积极的临床试验结果，增强了其在欧洲和日本的市场存在。预计每年盈利增长为 36.7%，研发专注于通过创新治疗解决罕见疾病，Pharming 正在将自己定位为专业医疗解决方案的关键参与者。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Pharming Group stock in this health report.</li>
<li>Understand Pharming Group's track record by examining our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁我们对 Pharming Group 股票分析的全面见解，详见此健康报告。</li>
<li>通过查看我们的历史报告了解 Pharming Group 的业绩记录。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0b975b67-eb09-4f0d-a0c0-7a08bd4f1141/chart/revenue-and-expenses-breakdown"/></p>
<p>ENXTAM:PHARM Revenue and Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月 ENXTAM:PHARM 收入和支出明细</p>
</div><h2>CELSYS (TSE:3663)</h2>
<div class="lb-trans"><h2>CELSYS (TSE:3663)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> CELSYS, Inc. operates in Japan providing content creation solutions and has a market cap of approximately ¥39.85 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CELSYS, Inc. 在日本运营，提供内容创作解决方案，市值约为 398.5 亿日元。</p>
</div><p><strong>Operations:</strong> The company focuses on providing content creation solutions in Japan. It generates revenue primarily through software sales and related services, with a notable emphasis on digital illustration and animation tools.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司专注于在日本提供内容创作解决方案，主要通过软件销售和相关服务产生收入，特别强调数字插图和动画工具。</p>
</div><p>CELYS has demonstrated resilience and strategic foresight in its financial operations, particularly evident in its recent corporate actions to optimize treasury shares. With a projected annual earnings growth of 22.3% and revenue increases at 9.7% per year, the company is outpacing the Japanese market average significantly. These figures are bolstered by robust R&amp;D investments that not only underscore CELSYS's commitment to innovation but also align with broader industry trends towards enhanced digital solutions. Recent dividend adjustments reflect a tactical approach to shareholder returns, balancing between reinvestment in growth and direct shareholder value enhancement through dividends expected to rise from JPY 14.00 to JPY 20.00 per share annually.</p>
<div class="lb-trans"><p>CELSYS 在其财务运营中展现出韧性和战略前瞻性，尤其体现在其最近的企业行动中，以优化库藏股。预计年盈利增长为 22.3%，收入年增长率为 9.7%，显著超过日本市场的平均水平。这些数据得益于强劲的研发投资，不仅突显了 CELSYS 对创新的承诺，还与行业向更先进数字解决方案的趋势相一致。最近的股息调整反映了对股东回报的战术性方法，在增长再投资和通过预计从每股 14.00 日元提高到 20.00 日元的股息直接提升股东价值之间取得平衡。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of CELSYS.</li>
<li>Review our historical performance report to gain insights into CELSYS''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 CELSYS 的完整分析健康报告。</li>
<li>查看我们的历史业绩报告，以获取 CELSYS 过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/850a7a11-e4be-477b-8270-7d157f2aada2/chart/earnings-and-revenue-growth"/></p>
<p>TSE:3663 Earnings and Revenue Growth as at May 2026</p>
<div class="lb-trans"><p>截至 2026 年 5 月 TSE:3663 盈利和收入增长</p>
</div><h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
<div class="lb-trans"><h2>Plus Alpha ConsultingLtd (TSE:4071)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Plus Alpha Consulting Co., Ltd. offers marketing and HR solutions within Japan, with a market capitalization of ¥92.33 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Plus Alpha Consulting Co., Ltd. 在日本提供市场营销和人力资源解决方案，市值为 923.3 亿日元。</p>
</div><p><strong>Operations:</strong> Plus Alpha Consulting Co., Ltd. generates revenue primarily through its HR solutions, which account for ¥13.84 billion, and marketing solutions, contributing ¥3.79 billion. The company operates exclusively within Japan's market, focusing on these two key segments to drive its business operations.</p>
<div class="lb-trans"><p><strong>运营：</strong> Plus Alpha Consulting Co., Ltd. 主要通过其人力资源解决方案产生收入，贡献 138.4 亿日元，以及市场营销解决方案，贡献 37.9 亿日元。该公司专注于日本市场，致力于这两个关键领域推动其业务运营。</p>
</div><p>Plus Alpha ConsultingLtd. has recently shown robust financial performance, with a notable increase in quarterly sales from JPY 3.89 billion to JPY 4.44 billion and a surge in net income from JPY 755.55 million to JPY 1.15 billion year-over-year. This growth trajectory is supported by an annual revenue growth rate of 12.5%, outpacing the Japanese market's average of 6%. The company's commitment to innovation is evident from its R&amp;D spending trends, aligning with industry shifts towards more sophisticated digital solutions and ensuring competitiveness in the evolving tech landscape.</p>
<div class="lb-trans"><p>Plus Alpha ConsultingLtd 最近展现出强劲的财务表现，季度销售额从 38.9 亿日元增加到 44.4 亿日元，净收入从 7.5555 亿日元激增至 11.5 亿日元，同比大幅增长。这一增长轨迹得益于 12.5% 的年收入增长率，显著超过日本市场的平均水平 6%。该公司对创新的承诺体现在其研发支出趋势上，与行业向更复杂数字解决方案的转变相一致，确保在不断发展的科技领域中的竞争力。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Plus Alpha ConsultingLtd's health report.</li>
<li>Learn about Plus Alpha ConsultingLtd's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索 Plus Alpha ConsultingLtd 健康报告中我们发现的详细信息。</li>
<li>了解 Plus Alpha ConsultingLtd 的历史表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a6c28592-bcb7-4305-8f5b-f6b1e621ab4b/chart/revenue-and-expenses-breakdown"/></p>
<p>TSE:4071 Revenue and Expenses Breakdown as at May 2026</p>
<div class="lb-trans"><p>TSE:4071 收入和支出明细截至 2026 年 5 月</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住机会</h2>
</div><ul>
<li>Click this link to deep-dive into the 197 companies within our Global High Growth Tech and AI Stocks screener.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们全球高增长科技和人工智能股票筛选器中的 197 家公司。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取有关您股票的新警告信号的提醒。</li>
<li>使用免费的 Simply Wall St 应用程序更智能地投资，提供全球每个股票市场的详细见解。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，这些公司得到了分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：</strong> 在一个地方管理您的所有股票投资组合</h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合助手</strong>，<strong>而且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看您的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新警告信号或风险的提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪您股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

2026 年 5 月值得关注的高增长科技股票